NEJM Journal Watch Dermatology Top Stories of 2015

Letter to Readers |
December 23, 2015

NEJM Journal Watch Dermatology Top Stories of 2015

  1. Hensin Tsao, MD, PhD

A perspective on the most important research in the field from the past year

  1. Hensin Tsao, MD, PhD

Dermatologists face tremendous challenges today. Changes to ICD-10 in October, the shifting landscape for maintenance of certification, the increased attention to meaningful use, and documentation for electronic medical records are just some of the practice gymnastics expected of practitioners of modern-day medicine. Fortunately, NEJM Journal Watch Dermatology is here to help with one of the tasks — keeping up with the literature.

Again, we are pleased to present our list of ten top stories published in dermatology research in the past year. A theme that has been on our list for the past few years is how mechanisms lead to medicines. Precision medicine has now entered the world of dermatomyositis with ruxolitinib. In addition, checkpoint therapies for all forms of metastatic melanoma have exploded onto the research and clinical stages. It is also nice to see head-to-head trials of therapeutics for psoriasis. Like you, our editors are practicing clinicians and know the difficulties of synthesizing and digesting the published literature. Rest assured that while you are completing your meaningful use and medication reconciliation, we are bringing you the most relevant literature for your practice.

Our NEJM Journal Watch Dermatology Top Stories of 2015, in no particular order, are:

Endurance of Survival Benefit with Ipilimumab Therapy for Advanced Melanoma

Nivolumab for BRAF-Wildtype Tumors

Tofacitinib vs. Etanercept for Moderate to Severe Psoriasis

Safety and Efficacy of Systemic Psoriasis Medications

The Janus Kinase Inhibitor Ruxolitinib Might Be Effective for Dermatomyositis

Headstrong Seborrheic Dermatitis

Erosive Vulvovaginal Lichen Planus: Criteria for Diagnosis

Allergic Contact Dermatitis Is a Common Problem in Nursing Personnel

Immunotherapies in Melanoma: Genomics Reveals Determinants of Response to Anti-CTLA4 Therapy

Dermatologists Infrequently Use Measures to Filter Cautery Smoke

From the NEJM Journal Watch Dermatology family to yours — a happy and wonderful 2016!

Editor Disclosures at Time of Publication

  • Disclosures for Hensin Tsao, MD, PhD at time of publication Consultant / advisory board Lubax; WorldCare Clinical Equity Lubax Grant / Research support NIH; Department of Defense; American Skin Association; Piramal Editorial boards British Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.